EUVIMEDOntdek EUVIMED
CrossrefInfokaart

Inhibitors of PIM‐1 Signaling Pathways as Anticancer Agents: Pharmacological and Structural Viewpoints

Banty Kumar, Ankur Vaidya, Shweta Jain, Sanjeev Kumar Sahu, Preeti Patel, Vivek Asati

ChemMedChem · 2026-10-28 · 21 (20)

DOI: 10.1002/cmdc.70533 ↗
SamenvattingBibliografische gegevens

Samenvatting

Pim‐1, a carcinogenic threonine and serine kinase, inhibits apoptosis and advances the cell cycle. It is overexpressed in several human cancers. The proviral integration site of Moloney murine leukemia virus 1 is Pim‐1. Previous studies have shown that the Pim‐1 30‐UTR regulates the stability of Pim‐1 mRNA. Threonine and serine are identified as the proto‐oncogene Pim‐1 kinase. Pim‐1 mediates numerous biological processes, including apoptosis, cell division, proliferation, and cancer. Pim‐1‐mediated anticancer activity has been reported in several analogs of thiazole/ bis ‐thiazole, tetrazine, thiophenes, quinoline, pyrazolopyrimidine, 3‐cyanopyridine, thiazolidine‐2,4‐dione, thieno[2,3‐ b ]pyridine, triazolo[4,3‐ b ]pyridazine, pyrazolo[1,5‐ a ]pyrimidines, and pyrazolo[3,4‐ b ]pyridine derivatives. Additionally, flavonoids and amino alcohol compounds that constitute Pim‐1‐mediated cancer therapy have also been identified thus far. Many compounds with Pim‐1‐mediated cytotoxicity have been discovered up to this point, and scientists are currently concentrating on bringing novel compounds with anticancer potential to the market.

Kennis die bij uw werk past.

Van een gratis start via persoonlijk literatuuronderzoek tot de volledige Research Suite.

Tarieven bekijken →

Zijn alle volledige uitgeversteksten inbegrepen?

Nee. Bibliografische records, abstracts en volledige teksten zijn verschillende inhoudstypen. Beschikbaarheid hangt af van bron, open access en bestaande licenties. Een EUVIMED-abonnement vervangt geen aanvullende uitgeversrechten.

Tarieven bekijken →